(VIANEWS) – CEGEDIM (CGM.PA) is among this list of stock assets with the highest dividend rate and return on equity on the Healthcare sector.
| Financial Asset | Price | Forward Dividend Yield | Return on Equity |
|---|---|---|---|
| CEGEDIM (CGM.PA) | €21.70 | 2.54% | 4.5% |
| MEDISTIM (MEDI.OL) | kr280.00 | 1.69% | 31.89% |
Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. CEGEDIM (CGM.PA)
2.54% Forward Dividend Yield and 4.5% Return On Equity
Cegedim SA operates as a technology and services company in the field of digital data flow management for healthcare ecosystem and B2B, and business software publisher for healthcare and insurance professionals in France, other European countries, and internationally. It operates in two segments, Health Insurance, HR and e-Services; and Healthcare Professionals. The Health Insurance, HR and e-Services segment markets various products and services to insurance companies, mutual insurers, personal protection insurers, and insurance brokers, as well as engages in the interactions between these entities and healthcare professionals. This segment also provides solutions for hosting, HR and payroll management outsourcing, electronic data exchange, and data processing services. The Healthcare Professionals division sells management software, databases, and solutions to doctors, allied health professionals, pharmacists, and healthcare facilities. The company was incorporated in 1969 and is headquartered in Boulogne-Billancourt, France. Cegedim SA is a subsidiary of FCB SA.
Earnings Per Share
As for profitability, CEGEDIM has a trailing twelve months EPS of €0.99.
PE Ratio
CEGEDIM has a trailing twelve months price to earnings ratio of 21.92. Meaning, the purchaser of the share is investing €21.92 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.5%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 5.2%, now sitting on 555.21M for the twelve trailing months.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, CEGEDIM’s stock is considered to be oversold (<=20).
More news about CEGEDIM.
2. MEDISTIM (MEDI.OL)
1.69% Forward Dividend Yield and 31.89% Return On Equity
Medistim ASA develops, produces, services, leases, and distributes medical devices for cardio-vascular surgery in the United States, Europe, Asia, and internationally. It offers MiraQ Cardiac, a system that combines ultrasound imaging and transit time flow measurement (TTFM) in a single system for cardiac surgery; MiraQ Vascular, a system that combines ultrasound imaging and transit TTFM in a single system for vascular surgery; and imaging probes for intraoperative use. The company also provides various flow probes, such as QuickFit TTFM probes to accurately measure blood volume flow intraoperatively in various range of surgical applications; Vascular TTFM probes for enhancing surgical outcomes; and doppler probes that are used on the surface of the heart/vessel to search for intramural coronary arteries or to locate the position and quantify the degree of a stenosis. In addition, it distributes and sells third party medical equipment. The company was incorporated in 1984 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, MEDISTIM has a trailing twelve months EPS of kr6.34.
PE Ratio
MEDISTIM has a trailing twelve months price to earnings ratio of 44.16. Meaning, the purchaser of the share is investing kr44.16 for every norwegian krone of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 31.89%.
Growth Estimates Quarters
The company’s growth estimates for the present quarter is a negative 17.7% and positive 11.1% for the next.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Apr 25, 2023, the estimated forward annual dividend rate is 4.5 and the estimated forward annual dividend yield is 1.69%.
More news about MEDISTIM.
